CAH
Cardinal Health
$222.74
▲ 0.4%Updated Today 7:15 PM ET
▲ Up 34.1% over the last 12 months
Market Cap
$51.94B
P/E
33.62x
Forward P/E (est.)
32.88x
ROE
37.2%
Revenue Growth
12.9%
EPS Growth
2.3%
Profit Margin
0.6%
FCF Yield
1.5%
Debt / Equity
3.48x
ROIC
—
Interest Coverage
10.58x
Current Ratio
0.91x
Dividend Yield
0.9%
Implied Growth (rev. DCF)
5.3%
Rating Score
39/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CAH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CAH trades near $222.74, above its 50-day average ($203.60) and 200-day average ($196.92). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 82 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. CAH's is $5.36 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CAH found buyers near $194.00 (support) and sellers near $229.78 (resistance); its 52-week range is $137.75–$233.60. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Cardinal Health (CAH) is a large-cap company in the Health Care Distributors industry, part of the Health Care sector of the S&P 500, with a market value around $51.94B.
In its latest reported year it generated about $222.58B in revenue and $1.56B in net profit.
Our model rates CAH Weak (39/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.2%
Revenue moved from $162.47B in 2021 to $222.58B in 2025, a 8.2% compound annual growth rate. The most recent year grew a steady 12.9% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
3.7%
Operating Margin
1.0%
Net Margin
0.7%
ROE
37.2%
Cardinal Health keeps about 0.6% of each sales dollar as net profit, with a 3.7% gross margin and 1.0% operating margin. Return on equity is 37.2%. Thin margins leave less cushion if costs rise.
Total Debt
$2.50B
Net Debt
-$275.00M
Net cash position
Net Debt / EBITDA
-0.12x
Debt / Equity
3.48x
Leverage: debt-to-equity is 3.5x, and operating profit covers interest about 10.6x, with a current ratio of 0.9x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $2.50B of total debt against $2.78B of cash.
Operating CF
$2.40B
Free Cash Flow
$1.85B
FCF Margin
0.8%
In the latest year Cardinal Health produced about $2.40B of operating cash flow and $1.85B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
33.62x
P/S
0.24x
P/B
9.01x
EV / EBITDA
17.31x
CAH trades at 33.6x trailing earnings (about 32.9x on estimated forward earnings), 0.2x sales, and 9.0x book value. Reverse-engineering today's price implies the market expects roughly 5.3% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How CAH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), CAH ranks #49 of 59 by our overall rating. It trades at a premium versus the sector on earnings (33.6x P/E vs. 25.4x median) with a higher return on equity (37.2% vs. 14.9%) and faster revenue growth (12.9% vs. 7.9%).
P/E vs sector
33.6x
median 25.4x
ROE vs sector
37.2%
median 14.9%
Growth vs sector
12.9%
median 7.9%
Sector rank
#49
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$1,045.62 – $1,777.56
vs. $222.74 today · expected CAGR 36% – 51%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $251.51B | $284.21B | $321.16B | $362.91B | $410.09B |
| Net income | $7.55B | $8.53B | $9.63B | $10.89B | $12.30B |
| EPS | $32.06 | $36.23 | $40.94 | $46.27 | $52.28 |
| Share price (low) | $641.30 | $724.67 | $818.87 | $925.33 | $1,045.62 |
| Share price (high) | $1,090.21 | $1,231.94 | $1,392.09 | $1,573.06 | $1,777.56 |
| CAGR (low–high) | 188% / 389% | 80% / 135% | 54% / 84% | 43% / 63% | 36% / 51% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CAH:
- Revenue is growing 12.9% a year, a sign of real demand.
- Strong return on equity (37.2%) shows capital is put to work well.
The case against CAH:
- Thin net margins (0.6%) leave little room for error.
- Elevated leverage (debt/equity 3.5x) adds financial risk.
- Our model's overall read is Weak (39/100).
Valuation risk — at 33.6x earnings, disappointing results could compress the multiple.
Balance-sheet risk — debt/equity of 3.5x magnifies the impact of higher rates or weaker earnings.
Margin risk — thin profitability (0.6%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Cardinal Health is a large-cap health care business still growing nicely, with modest profitability, and a heavier debt load to watch. It trades at 33.6x earnings, which our model scores Weak (39/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.